Taysha Gene Therapies Announces Positive Clinical Data Across ...

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, ...

Taysha Gene Therapies Announces Oral Presentation on TSHA-102 ...

The presentation will entail previously disclosed positive clinical data up to 52 weeks from the ongoing REVEAL Phase 1/2 adolescent and ...

Taysha Seeks to Overturn Natural History Trends With Rett ...

... Taysha-Gene-Therapies-Provides-Update-on-Deprioritized-Pipeline-Programs.html 5. Taysha Gene Therapies announces positive clinical data across ...

General - Taysha Gene Therapies

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials ...

Taysha's Rett Syndrome Gene Therapy TSHA-102 Continues to ...

... taysha-gene-therapies-announces-positive-clinical-data-across 2. Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy ...

Phase 1/2 Studies Highlight Durable Impacts of Gene Therapy ...

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 ...

Release Details - Taysha Gene Therapies

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome.

Taysha Gene Therapies to Present Biodistribution Data from an ...

... therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the ...

Taysha Gene Therapies, Inc. (TSHA) - Yahoo Finance

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials ...

Taysha Gene Therapies Announces Positive Recommendation

Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on ...

Taysha Gene Therapies Announces Positive Initial Biomarker Data ...

“TSHA-101 is the first bicistronic vector in clinical development, representing an important first for the field of gene therapy,” noted RA ...

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical ...

REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company's ...

Taysha Gene Therapies Announces Updates to TSHA-102

REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company's ...

Taysha Gene Therapies Announces Positive Preliminary Clinical ...

Taysha Gene Therapies, Inc. today announced preliminary clinical safety data for the first-generation construct in CLN7 disease.

Taysha Gene Therapies to Present Clinical Data from Both REVEAL ...

Elsa Rossignol and Dr. Colleen Buhrfiend. The webcast can be accessed via Taysha's website. Positive. Taysha to present new clinical ...

Taysha Gene Therapies Announces New Data on Multiple ...

TSHA-113 significantly reduced tau mRNA and protein levels in mouse models of human tauopathies via cerebral spinal fluid (CSF) delivery ...

Taysha Gene Therapies to Present Clinical Data from Both REVEAL ...

The live webcast and replay will be available through Taysha's website here. 2024 IRSF Rett Syndrome Scientific Meeting Presentation Details

Taysha Gene Therapies (@TayshaGTx) / X

... #Rettsyndrome. Learn more: https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-positive-clinical-data-across… Image. 1.

Taysha Gene Therapies - Recent News & Activity - Crunchbase

Taysha Gene Therapies announces positive clinical data across adult and pediatric patients from low dose cohort in ongoing.